(Q47847736)

6 February 2018

title

What will a partly protective malaria vaccine mean to mothers in Africa? (English)

1 reference

6 February 2018

0 references

1 reference

Judith E Epstein

1

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 November 2007

1 reference

6 February 2018

published in

The Lancet

1 reference

6 February 2018

volume

370

1 reference

6 February 2018

issue

9598

1 reference

6 February 2018

page(s)

1523-1524

1 reference

6 February 2018

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961642-0

7 January 2021

10.1016/S0140-6736(07)61642-0

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018